Display Settings:

Format

Send to:

Choose Destination
    Eur J Cancer. 1991;27(12):1639-42.

    Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].

    Source

    MRC Clinical Oncology, Radiotherapeutics Unit, Cambridge, U.K.

    Erratum in

    • Eur J Cancer 1992;28(2-3):616.

    Abstract

    A novel non-immunosuppressive cyclosporin [corrected], PSC-833, has been tested for its ability to circumvent resistance to doxorubicin, vincristine and colchicine in human and murine multidrug resistant (MDR) cell lines. This compound is shown to be a highly potent resistance modifier, being 7-10-fold more potent than the parent compound, cyclosporin A, whilst approximately equal to cyclosporin A in the growth inhibitory effects of compound alone. Reversal of the P-glycoprotein-associated MDR drug accumulation defect is a major component of resistance reversal for PSC-833, as it is for cyclosporin A.

    PMID:
    1816768
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk